Literature DB >> 18299682

Update on autosomal dominant polycystic kidney disease.

V E Torres1, S Rossetti, P C Harris.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent, potentially lethal monogenic disorder. Over the past two decades, its study has yielded remarkable progress. The mutated genes have been identified by positional cloning, the function of a novel class of conserved proteins encoded by these genes has been partially elucidated, and a neglected organelle, the primary cilium, has become the focus of investigation. The large inter- and intra-familial variability, explained to a large extent by genetic heterogeneity and modifier genes, is now better appreciated. Increased understanding of the progression of the disease and of its underlying genetic, molecular and cellular mechanisms have laid the foundations for the development of potentially effective therapies and clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 18299682

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  5 in total

1.  A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.

Authors:  Murali K Yanda; Qiangni Liu; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2018-06-06       Impact factor: 5.157

2.  The Mitochondrial Ca2+ import complex is altered in ADPKD.

Authors:  Murali K Yanda; Vartika Tomar; Robert Cole; William B Guggino; Liudmila Cebotaru
Journal:  Cell Calcium       Date:  2021-11-19       Impact factor: 6.817

3.  Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease.

Authors:  Murali K Yanda; Qiangni Liu; Valeriu Cebotaru; William B Guggino; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

Review 4.  A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.

Authors:  Claire Woon; Ashleigh Bielinski-Bradbury; Karl O'Reilly; Paul Robinson
Journal:  BMC Nephrol       Date:  2015-08-15       Impact factor: 2.388

5.  A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells.

Authors:  Rosita R Asawa; Carina Danchik; Alexey Zakharov; Yuchi Chen; Ty Voss; Ajit Jadhav; Darren P Wallace; Josephine F Trott; Robert H Weiss; Anton Simeonov; Natalia J Martinez
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.